Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMMBNASDAQ:LGVNNASDAQ:LMDXNASDAQ:RLMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMMBChemomab Therapeutics$1.37+0.4%$1.20$0.78▼$2.55$19.60M0.55211,574 shs133,868 shsLGVNLongeveron$1.35-1.8%$1.51$0.77▼$6.40$20.15M0.382.97 million shs51,082 shsLMDXLumiraDx$0.01$0.02▼$1.33$5.10M1.7356.75 million shs132.24 million shsRLMDRelmada Therapeutics$0.64+4.0%$0.37$0.24▼$4.47$21.22M0.18931,280 shs742,653 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMMBChemomab Therapeutics+0.37%-0.36%+13.75%-20.18%+62.50%LGVNLongeveron-1.82%-4.93%-16.15%-13.46%+16.38%LMDXLumiraDx0.00%0.00%0.00%0.00%0.00%RLMDRelmada Therapeutics+3.97%+38.70%-7.33%+116.75%-79.31%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCMMBChemomab Therapeutics3.0393 of 5 stars3.55.00.00.01.41.71.3LGVNLongeveron3.2696 of 5 stars3.65.00.00.01.91.71.3LMDXLumiraDxN/AN/AN/AN/AN/AN/AN/AN/ARLMDRelmada Therapeutics4.4167 of 5 stars3.02.00.04.43.64.21.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMMBChemomab Therapeutics 3.00Buy$8.50522.71% UpsideLGVNLongeveron 3.25Buy$8.67541.98% UpsideLMDXLumiraDx 0.00N/AN/AN/ARLMDRelmada Therapeutics 2.00Hold$4.25564.69% UpsideCurrent Analyst Ratings BreakdownLatest LMDX, LGVN, CMMB, and RLMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025CMMBChemomab TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$11.00 ➝ $10.003/21/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/3/2025LGVNLongeveronHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMMBChemomab TherapeuticsN/AN/AN/AN/A$1.54 per shareN/ALGVNLongeveron$2.23M9.06N/AN/A$2.68 per share0.50LMDXLumiraDx$126.52M0.00N/AN/A($0.33) per share0.00RLMDRelmada TherapeuticsN/AN/AN/AN/A$2.84 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMMBChemomab Therapeutics-$24.22M-$0.76N/AN/AN/AN/A-101.70%-76.18%N/ALGVNLongeveron-$21.41M-$6.28N/AN/AN/A-967.49%-142.43%-100.84%N/ALMDXLumiraDx-$447.79M-$1.09N/AN/AN/A-268.45%N/A-77.91%N/ARLMDRelmada Therapeutics-$98.79M-$2.51N/AN/AN/AN/A-129.80%-112.06%8/6/2025 (Estimated)Latest LMDX, LGVN, CMMB, and RLMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CMMBChemomab Therapeutics-$0.20-$0.14+$0.06-$0.14N/AN/A5/12/2025Q1 2025RLMDRelmada Therapeutics-$0.31-$0.58-$0.27-$0.58N/AN/A3/27/2025Q4 2024RLMDRelmada Therapeutics-$0.70-$0.62+$0.08-$0.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMMBChemomab TherapeuticsN/AN/AN/AN/AN/ALGVNLongeveronN/AN/AN/AN/AN/ALMDXLumiraDxN/AN/AN/AN/AN/ARLMDRelmada TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMMBChemomab TherapeuticsN/A4.574.57LGVNLongeveronN/A7.677.67LMDXLumiraDxN/A0.450.23RLMDRelmada TherapeuticsN/A6.896.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMMBChemomab Therapeutics46.05%LGVNLongeveron10.01%LMDXLumiraDx9.59%RLMDRelmada Therapeutics45.24%Insider OwnershipCompanyInsider OwnershipCMMBChemomab Therapeutics11.91%LGVNLongeveron19.12%LMDXLumiraDx35.41%RLMDRelmada Therapeutics20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMMBChemomab Therapeutics2014.36 million12.65 millionNot OptionableLGVNLongeveron2014.93 million12.00 millionNot OptionableLMDXLumiraDx1,210318.55 million205.75 millionNot OptionableRLMDRelmada Therapeutics1033.19 million24.74 millionOptionableLMDX, LGVN, CMMB, and RLMD HeadlinesRecent News About These CompaniesRelmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in StockMay 21 at 7:11 AM | insidertrades.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comRelmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 12, 2025 | globenewswire.comRelmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025May 8, 2025 | globenewswire.comRelmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder CancerApril 28, 2025 | nasdaq.comRelmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025April 28, 2025 | globenewswire.comRelmada Therapeutics to hold a virtual meetingApril 27, 2025 | markets.businessinsider.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 27, 2025 | globenewswire.comRelmada Therapeutics to Host KOL Event on Phase 2 NDV-01 DataApril 24, 2025 | globenewswire.comUPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics To Present NDV-01 Data at AUA2025April 14, 2025 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call TranscriptMarch 29, 2025 | msn.comQ4 2024 Relmada Therapeutics Inc Earnings CallMarch 29, 2025 | uk.finance.yahoo.comRelmada reconsiders phase 2 plans to test magic mushroom extract for obesityMarch 28, 2025 | fiercebiotech.comRelmada Therapeutics reports Q4 EPS (62c) vs. (84c) last yearMarch 28, 2025 | markets.businessinsider.comRelmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone developmentMarch 28, 2025 | msn.comRelmada Therapeutics, Inc. (RLMD) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comRelmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business UpdateMarch 27, 2025 | globenewswire.com4RLMD : Insights Ahead: Relmada Therapeutics's Quarterly EarningsMarch 27, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLMDX, LGVN, CMMB, and RLMD Company DescriptionsChemomab Therapeutics NASDAQ:CMMB$1.36 +0.01 (+0.37%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$1.42 +0.05 (+4.03%) As of 05/23/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). The company was formerly known as Anchiano Therapeutics Ltd. and changed its name to Chemomab Therapeutics Ltd. in March 2021. Chemomab Therapeutics Ltd. was founded in 2011 and is based in Tel Aviv, Israel.Longeveron NASDAQ:LGVN$1.35 -0.03 (-1.82%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.36 +0.01 (+1.11%) As of 05/23/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.LumiraDx NASDAQ:LMDXLumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.Relmada Therapeutics NASDAQ:RLMD$0.64 +0.02 (+3.97%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$0.61 -0.03 (-4.13%) As of 05/23/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Alphabet Gets JPMorgan’s Vote of Confidence After Google I/O Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
